Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) presents a significant therapeutic challenge.
• Recent years have seen the approval of multiple novel agents for r/r DLBCL.
• These agents target critical signaling pathways and cell surface proteins in malignant B-cells.

Purpose of the Study:

• To review and discuss novel therapeutic agents for relapsed/refractory Diffuse Large B-cell Lymphoma.
• To analyze therapies targeting key intracellular signaling pathways.
• To highlight novel agents targeting extracellular proteins and their clinical impact.

Main Methods:

• Literature review of approved and emerging therapies for r/r DLBCL.
• Analysis of targeted pathways including B-cell receptor (BCR), Toll-Like Receptor (TLR), PI3K/AKT/mTOR, BCL-2, and XPO-1.
• Examination of therapies targeting extracellular proteins such as CD19, CD20, CD30, ROR1, and PD-1.

Main Results:

• Multiple novel agents targeting specific signaling pathways have demonstrated efficacy in r/r DLBCL.
• Therapies directed at extracellular targets like CD19 and CD20 have shown significant clinical benefit.
• Emerging agents targeting BCL-2 and XPO-1 represent promising avenues for treatment.

Conclusions:

• A growing armamentarium of targeted therapies offers new hope for patients with r/r DLBCL.
• Understanding the mechanisms of action and resistance is crucial for optimizing treatment strategies.
• Continued research into novel pathways and combinations is essential to improve outcomes in DLBCL.